SCHEMBL684388

SCHEMBL684388

CC1(C)CCOCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10187702 0.87
SCHEMBL8471500 0.81 KDM4E (0.31)
SCHEMBL441721 0.79
Fluoride SCHEMBL28317530 0.78
SCHEMBL16297795 0.77
SCHEMBL8480452 0.74 KDM4E (0.31)
SCHEMBL5432 0.73
SCHEMBL8397539 0.73
SCHEMBL23229930 0.73 MEN1 (0.43)
Isobutane SCHEMBL586014 0.72 LMNA (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 456 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260138998-A1 GLP-1 RECEPTOR AGONISTS AND METHODS OF USE MERCK SHARP & DOHME LLC (US) 2026-05-21 US disclosed
US-20260109715-A1 IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY (JP) 2026-04-23 US disclosed
EP-4674879-A1 CATIONIC POLYMERIZATION INITIATOR COMPOSITION, AND METHOD FOR PRODUCING OXYMETHYLENE COPOLYMER AND MOLDED ARTICLE USING SAME MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2026-01-07 EP disclosed
US-12398136-B2 Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors VENTUS THERAPEUTICS U.S., INC. (US) 2025-08-26 US disclosed
US-12331048-B2 Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors VENTUS THERAPEUTICS U.S., INC. (US) 2025-06-17 US disclosed
US-20250002479-A1 PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2025-01-02 US disclosed
US-12172984-B2 Pyrazolopyridine derivatives and uses thereof NOVARTIS AG (CH) 2024-12-24 US disclosed
US-20240409540-A1 PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 INHIBITORS VENTUS THERAPEUTICS U S INC (US) 2024-12-12 US disclosed
US-20240383896-A1 PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 INHIBITORS VENTUS THERAPEUTICS U.S., INC. 2024-11-21 US disclosed
US-20240382457-A1 BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS NOVARTIS PHARMA AG (CH) 2024-11-21 US disclosed
US-20070049536-A1 Novel compounds as inhibitors of hepatitis C virus NS3 serine protease SCHERING CORPORATION 2007-03-01 US disclosed
US-7183293-B2 Ether derivatives useful as inhibitors of PDE4 isozymes PFIZER INC. (US) 2007-02-27 US disclosed
US-20070042968-A1 Sulfur compounds as inhibitors of Hepatitis C virus NS3 serine protease SCHERING CORPORATION 2007-02-22 US disclosed
US-20070032433-A1 Novel peptides as NS3-serine protease inhibitors of hepatitis C virus SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. 2007-02-08 US disclosed
US-20070010453-A1 Prodrugs of GABA analogs, compositions and uses thereof XENOPORT, INC. 2007-01-11 US disclosed
US-20070010453-A1 Prodrugs of GABA analogs, compositions and uses thereof XENOPORT, INC. 2007-01-11 US disclosed
WO-2006113942-A2 METHOD OF INHIBITING CATHEPSIN ACTIVITY SCHERING CORPORATION (US) 2006-10-26 WO disclosed
US-20040077553-A1 Prodrugs of GABA analogs, compositions and uses thereof XENOPORT, INC. 2004-04-22 US disclosed
CN-1114599-C Process for preparing dihydropyrane compound KAO CORP (JP) 2003-07-16 CN disclosed
CN-1180701-A Process for preparing dihydropyrane compound KAO CORP (JP) 1998-05-06 CN disclosed